Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM POLYSTYRENE SULFONATE vs LOKELMA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium polystyrene sulfonate is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the large intestine, thereby reducing serum potassium levels.
Patiromer, a non-absorbed potassium-binding polymer, exchanges calcium for potassium ions in the gastrointestinal tract, thereby increasing fecal potassium excretion and lowering serum potassium levels.
Treatment of hyperkalemia
Treatment of hyperkalemia,Off-label: Management of hyperkalemia in patients with chronic kidney disease on renin-angiotensin-aldosterone system inhibitors
Adults: 15 g orally once daily to four times daily, as a single dose or suspension in water or syrup (3-4 m L per gram of resin). May also be administered rectally as a retention enema: 30-50 g every 6-8 hours, retained for at least 30-60 minutes.
5 g (one packet) orally three times daily; titrate to maintain serum potassium 4.0-5.0 m Eq/L; maximum 15 g three times daily (45 g/day).
The terminal elimination half-life of the absorbed fraction is not well-defined due to minimal systemic absorption; hence, half-life is not clinically relevant. The resin itself is not eliminated from the body via metabolism or excretion but is passed in feces.
Not applicable as LOKELMA is not systemically absorbed; terminal half-life is not measurable in traditional sense. Clinical effect duration correlates with gastrointestinal transit time (~6-8 hours for peak potassium lowering).
Sodium polystyrene sulfonate is not absorbed systemically; it acts locally in the gastrointestinal tract.
Patiromer is not absorbed systemically and not metabolized; it is excreted unchanged in feces.
Primarily fecal (via gut) as the resin is not absorbed. Only a small fraction (approximately 0.5-1% of the administered dose) is absorbed, and the absorbed portion is eliminated renally as the sulfonate moiety. Renal elimination contributes minimally to total clearance (<1%).
Primarily eliminated unchanged in feces (approximately 90%) via gastrointestinal transit; <1% excreted in urine as absorbed sodium zirconium cyclosilicate is negligible.
Negligible (<1%). The resin is not absorbed; therefore, protein binding of the intact resin is not applicable. The absorbed sulfonate moiety has negligible protein binding.
Not bound to plasma proteins as it is non-absorbed and acts locally in the gastrointestinal tract.
Not applicable (Vd essentially 0 for the resin as it remains in the GI tract). For the absorbed fraction, Vd is minimal (<0.1 L/kg) due to rapid renal excretion.
Not applicable (locally acting, non-absorbed); apparent Vd is negligible due to lack of systemic absorption.
Oral: Essentially 0% absorbed (non-absorbable resin). Rectal: Similarly, systemic absorption is negligible (<0.5%).
Oral bioavailability is <1% as the drug is not absorbed from the gastrointestinal tract.
No specific dose adjustment is recommended based on GFR; however, use with caution in patients with renal impairment due to risk of electrolyte abnormalities and colonic necrosis. Alternative potassium-lowering agents are preferred in severe renal disease.
No dose adjustment required based on GFR; monitor serum potassium more frequently in patients with e GFR <30 m L/min/1.73m² due to increased risk of hypokalemia.
No specific Child-Pugh-based dose modifications are established. Use with caution in patients with hepatic impairment due to potential for fluid and electrolyte disturbances.
No dose adjustment required for Child-Pugh Class A, B, or C; use with caution in severe hepatic impairment due to limited data.
Children: 1 g/kg orally per dose, given 1-4 times daily, or rectally as a retention enema: 1 g/kg per dose every 6-8 hours. Adjust based on serum potassium levels and body weight.
Safety and efficacy not established in pediatric patients; no approved dosing recommendations.
Elderly patients may be more susceptible to electrolyte imbalances and dehydration. Use the lowest effective dose and monitor serum potassium and sodium closely. Consider alternative therapy if risk of bowel ischemia or constipation is high.
No specific dose adjustment; monitor serum potassium and renal function due to age-related decline in renal function and increased risk of hypokalemia.
No FDA black box warning.
None
Risk of intestinal necrosis, particularly with concomitant use of sorbitol,Electrolyte disturbances (hypokalemia, hypocalcemia, hypomagnesemia),Sodium overload in patients with heart failure or hypertension,Use with caution in patients with severe constipation or impaction,Potential for aspiration if given orally to patients with impaired gag reflex
WARNING: Risk of hypomagnesemia; monitor serum magnesium. WARNING: Potential for gastrointestinal obstruction or perforation; use with caution in patients with severe gastrointestinal disorders. WARNING: May bind to other oral medications; separate dosing by at least 3 hours (or 6 hours for certain drugs).
Hypersensitivity to sodium polystyrene sulfonate or any component,Obstructive bowel disease,Neonates with reduced gut motility (especially when given with sorbitol),Severe hypokalemia
Absolute: Hypersensitivity to patiromer or any excipient. Relative: Severe constipation, bowel obstruction, or impaction; postoperative gastrointestinal surgery.
Avoid foods high in potassium (e.g., bananas, oranges, potatoes, spinach, avocados) and high-sodium foods to optimize potassium removal and prevent sodium overload. Do not mix SPS with juices containing potassium (e.g., orange juice). Maintain adequate fluid intake unless fluid-restricted. Avoid laxative use. No specific interaction with alcohol, but excess alcohol can affect electrolyte balance.
LOKELMA should be taken with food to reduce gastrointestinal side effects. No specific food restrictions, but high-potassium foods should be avoided as per dietary guidelines for hyperkalemia.
No adequate studies in pregnant women. Animal reproduction studies not conducted. Sodium polystyrene sulfonate is not absorbed systemically, so fetal exposure is minimal. However, potential maternal electrolyte disturbances (e.g., hypokalemia) may indirectly affect the fetus. Risk cannot be ruled out; use only if clearly needed.
No human studies. Animal reproduction studies not conducted. Insufficient data in pregnant women. Risk cannot be excluded. Due to mechanism (potassium binder, non-absorbed polymer), systemic absorption is minimal; fetal exposure unlikely. However, no controlled data. Use only if clearly needed and potential benefit justifies potential risk to fetus.
Not absorbed systemically; excretion into breast milk is unlikely. However, consider potential effects on infant electrolyte balance if maternal electrolyte disturbances occur. No M/P ratio available; use with caution in breastfeeding women.
No data on presence in human milk, effects on breastfed infant, or on milk production. Given negligible oral absorption, excretion into breast milk is expected to be minimal. Caution advised; consider developmental and health benefits of breastfeeding alongside mother's clinical need.
No specific dose adjustments required due to pregnancy-related pharmacokinetic changes, as drug is not absorbed. Administer same dose as for nonpregnant adults, but monitor electrolytes closely.
No pharmacokinetic studies in pregnancy. No dose adjustment recommended based on current data. Use lowest effective dose to normalize potassium levels. Monitor potassium closely as pregnancy may alter electrolyte balance.
Sodium polystyrene sulfonate (SPS) exchanges sodium for potassium in the colon. Onset of action is 2-12 hours (oral) or 30-60 minutes (rectal). Monitor for hypokalemia, hypomagnesemia, and sodium overload, especially in patients with renal impairment, heart failure, or hypertension. Do not administer orally in patients with impaired bowel motility (e.g., postoperative ileus, constipation) due to risk of colonic necrosis. Concurrent use with sorbitol increases risk of intestinal necrosis; avoid sorbitol-containing formulations. SPS is less effective than newer potassium binders (patiromer, sodium zirconium cyclosilicate). Rectal administration is preferred when rapid effect needed, but ensure enema is retained for at least 30-60 minutes. Each gram of SPS exchanges approximately 1 m Eq of potassium but also delivers 1 m Eq of sodium, which can worsen fluid overload.
LOKELMA (patiromer) is a non-absorbed potassium-binding polymer indicated for hyperkalemia. Administer at least 6 hours apart from other oral medications due to potential binding. Monitor serum potassium weekly until stable. May cause hypomagnesemia; check magnesium levels periodically. Use with caution in patients with gastrointestinal motility disorders.
Take this medication exactly as prescribed, usually 1 to 4 times daily.,For oral suspension, mix the powder with water or another liquid (not juice) as directed and drink immediately. Do not mix with orange juice or other potassium-containing liquids.,Do not take this medication within 3 hours of any other oral medication to prevent absorption issues.,This medication may cause constipation or stomach upset. Tell your doctor if you have severe constipation, rectal bleeding, or severe stomach pain.,Avoid using laxatives or stool softeners unless directed by your doctor due to increased risk of bowel problems.,This drug exchanges sodium for potassium, so it may increase your sodium levels. Monitor salt intake if you have high blood pressure or heart failure.,Contact your doctor immediately if you experience muscle weakness, irregular heartbeat, or signs of low potassium (e.g., confusion, leg cramps).,Keep this medication out of reach of children and do not use if the powder has changed color or consistency.
Take LOKELMA exactly as prescribed, usually once daily with food.,Separate LOKELMA from other oral medications by at least 6 hours.,Do not crush, chew, or open capsules; swallow whole.,Notify your doctor if you experience constipation, nausea, or stomach pain.,Do not stop taking LOKELMA without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM POLYSTYRENE SULFONATE vs LOKELMA, answered by our medical review team.
SODIUM POLYSTYRENE SULFONATE is a Potassium Binder that works by Sodium polystyrene sulfonate is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the large intestine, thereby reducing serum potassium levels.. LOKELMA is a Potassium Binder that works by Patiromer, a non-absorbed potassium-binding polymer, exchanges calcium for potassium ions in the gastrointestinal tract, thereby increasing fecal potassium excretion and lowering serum potassium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM POLYSTYRENE SULFONATE and LOKELMA depend on the specific clinical indication. These are both Potassium Binder agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM POLYSTYRENE SULFONATE is: Adults: 15 g orally once daily to four times daily, as a single dose or suspension in water or syrup (3-4 m L per gram of resin). May also be administered rectally as a retention enema: 30-50 g every 6-8 hours, retained for at least 30-60 minutes.. The standard adult dose of LOKELMA is: 5 g (one packet) orally three times daily; titrate to maintain serum potassium 4.0-5.0 m Eq/L; maximum 15 g three times daily (45 g/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM POLYSTYRENE SULFONATE and LOKELMA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM POLYSTYRENE SULFONATE is classified as Category C. No adequate studies in pregnant women. Animal reproduction studies not conducted. Sodium polystyrene sulfonate is not absorbed systemically, so fetal exposure is minimal. However, . LOKELMA is classified as Category C. No human studies. Animal reproduction studies not conducted. Insufficient data in pregnant women. Risk cannot be excluded. Due to mechanism (potassium binder, non-absorbed polymer). Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.